Spanish Breast Cancer Research Group
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.geicam.org
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
- Conditions
- Locally Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 2
- Registration Number
- NCT05744375
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 13
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario Reina Sofía, Córdoba, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
- Conditions
- Hormone Receptor PositiveHER2 Positive Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 177
- Registration Number
- NCT05252988
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
🇪🇸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
Registry Study of Pregnancy and Breast Cancer
- Conditions
- Breast Cancer and Pregnancy
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1000
- Registration Number
- NCT04603820
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain
Healthy Lifestyles and Quality of Life in Women With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 801
- Registration Number
- NCT04379908
- Locations
- 🇪🇸
Complejo Hospitalario de Jaén, Jaen, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Galicia, Spain
Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 32
- Registration Number
- NCT04370522
- Locations
- 🇪🇸
Hospital General Universitario Morales Meseguer, Murcia, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Conditions
- Early Breast Cancer
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 200
- Registration Number
- NCT04293393
- Locations
- 🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients
- Conditions
- Luminal BBreast Cancer
- Interventions
- Other: ExerciseOther: Stretching
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 12
- Registration Number
- NCT03860740
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis
- Conditions
- Breast Carcinoma Metastatic to the Bone
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 241
- Registration Number
- NCT03847220
- Locations
- 🇪🇸
Hospital de Barbastro, Barbastro, Huesca, Spain
🇪🇸Hospital Universitari Clinic I Provincial, Barcelona, Cataluña, Spain
🇪🇸Hospital Universitario Virgen Del Rocío, Sevilla, Andalucia, Spain